~~<i id='EFF425312F'><strike id='EFF425312F'><tt id='EFF425312F'><pre id='EFF425312F'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：hotspot 2025-09-29 22:05:15 Page View：6

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hey, doctors: Don't be no
Next article： ChatGPT in medicine: STAT answers readers' burning questions

leisure time

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

SurveillancevideoofPhilanaHolmesreachingfortwoHappyMealsinthedrive-thruatMcDonald'sisshownonacourtro

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

GaviCEOSethBerkleyissteppingdownatthestartofnextmonth.FABRICECOFFRINI/AFPviaGettyImagesSethBerkley,t